Bhanvi Satija
U.S. Health & Pharma Sector Specialist at Reuters
Covering U.S. Health and Pharma for Reuters. Views expressed are my own. RTs ≠ endorsements. Sporadic Twitter-er.
Articles
-
1 week ago |
today.westlaw.com | Bhanvi Satija |Anil D'Silva |Bill Berkrot |Patrick Wingrove
(Reuters) -Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell roughly 10% on investor worries that the...
-
1 week ago |
pharma.economictimes.indiatimes.com | Bhanvi Satija |Patrick Wingrove
Bengaluru: Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell roughly 10% on investor worries that the move could blunt its sales momentum. Lilly's leading position in weight loss and diabetes treatments has boosted its market value to more than $800 billion, making it the world's most valuable healthcare company.
-
1 week ago |
unionleader.com | Bhanvi Satija
Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of medicines it covers for reimbursement, but shares of the drugmaker still fell roughly 10% on investor worries that the move could blunt its sales momentum. Lilly's leading position in weight loss and diabetes treatments has boosted its market value to more than $800 billion, making it the world's most valuable healthcare company.
-
1 week ago |
yahoo.com | Bhanvi Satija |Patrick Wingrove
By Bhanvi Satija and Patrick Wingrove(Reuters) -Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity drug Zepbound from the list of medicines it covers for reimbursement dragged shares down over 5%.
-
2 weeks ago |
jp.reuters.com | Bhanvi Satija |Mariam Sunny
[３０日 ロイター] - スイス製薬大手ノバルティス (NOVN.S), opens new tabは、米同業レグラス・セラピューティクス(RGLS.O), opens new tabを最大１７億ドルで買収することで合意した。これによりノバルティスはレグラスが開発中の腎疾患治療薬「ファラブルセン」を入手することになる。 レグラスは３０日、ノバルティスの買収条件について、１株当たり７ドル、全体では約８億ドルの現金を前払いし、ファラブルセンが規制当局の承認を得た場合、レグラスの株主にさらに１株当たり７ドルを支払うと説明した。買収提示額はレグラス株の直近の終値に約１０８％上乗せした水準。 この買収でノバルティスは開発中の腎臓病薬群の強化が期待できる。このほかマイクロＲＮＡと呼ばれる遺伝物質の一種を標的にした治療薬を開発するレグラス独自のプラットフォームも利用できるようになる。 ファラブルセンは常染色体優性多発性嚢胞腎（のうほうじん）の治療薬として年内に後期臨床試験段階に入る予定。...
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 548
- Tweets
- 1K
- DMs Open
- No
RT @appadappajappa: In the next couple of decades, we are going to have a great number of single women in their 30s. Our society is not rea…
RT @Reuters_Health: A World Health Organization official on Thursday called for stronger surveillance in animals for evidence of infection…
RT @Reuters_Health: Roche will acquire California-based biopharmafirm Poseida Therapeutics for $9 per share at closing, for a total equity…